CTRI/2021/12/038477已完成未知
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 233
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Male and female patients, aged ââ?°Â¥18 years, diagnosed with chronic open-angle glaucoma or ocular hypertension, who in the opinion of the Investigator, were insufficiently controlled on monotherapy of topical beta-blockers.
- •2.Mean IOP measurements in at least 1 eye, the same eye(s), must have been:
- •Ã¢â?¬Â¢Ã¢â?°Â¥ 24 mmHg and ââ?°Â¤ 36 mmHg at the 9 a.m. time point, and
- •Ã¢â?¬Â¢Ã¢â?°Â¥ 21 mmHg and ââ?°Â¤ 36 mmHg at the 11 a.m. time point at both the Eligibility 1 and Eligibility 2, visits following washout of any IOP lowering medication
- •Ã¢â?¬Â¢Mean IOP must not have been > 36 mmHg in either eye at any time point.
- •3.Best corrected visual acuity (BCVA) of 20/100 or better in each eye.
- •4.Adequate wash-out period prior to baseline of any ocular hypotensive medication (see Table 1). In order to minimize potential risk to patients due to IOP elevations during the washout period, investigator may choose to gradually withdraw the ongoing ocular hypotensive medication and substitute a parasympathomimetic or carbonic anhydrase inhibitor (having shorter washout period) in place of sympathomimetics, alpha-agonist, beta-adrenergic blocking agent, topical prostaglandins and topical prostamides (having longer washout period) as per table 1. However, patients must have discontinued all ocular hypotensive medication for the minimum washout period provided in Table 1. In case the patient was being treated with any ocular hypotensive medication containing two drugs, washout period of the drug having a longer washout period should be considered as washout period (e.g. combination of pilocarpine and betaxolol); where the washout should be considered as 4 weeks).
- •5.Patients must have provided IEC approved written informed consent using the latest version of the IEC informed consent form.
- •6.Patients must be in good health and free from any clinically significant disease apart from indication under study.
- •7.Patients able to comply with study procedures in the opinion of the investigator.
- •8.Study patients must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required scheduled study visits.
- •9.Patients must be able to safely discontinue use of all ocular hypotensive medication(s) and undergo appropriate washout period.
- •10.Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy [including oral, transdermal, or implanted contraceptives (any hormonal method in conjunction with a secondary method), intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile (at least 6 months prior to study drug administration) sexual partner] for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
排除标准
- •1.Pregnant or lactating females.
- •2.Chronic, recurrent or severe inflammatory eye disease.
- •3.Severe central visual field loss (i.e., sensitivity ââ?°Â¤10 dB in ââ?°Â¥2 of the 4 visual field test points closest to the point of fixation) in either eye.
- •4.Schaffer angle grade <2 in either eye (as measured by gonioscopy).
- •5.Cup-to-disc ratio >0.80 (horizontal or vertical measurement) in either eye.
- •6.Unable to safely discontinue IOP-lowering ocular medications per the washout schedule.
- •7.Current or history within 3 months prior to baseline of significant ocular disease, e.g., corneal edema, uveitis, ocular infection, ocular inflammation in either eye.
- •8.Ocular trauma within the preceding 6 months.
- •9.Contraindication to brimonidine tartrate, timolol or sulfonamide therapy or known hypersensitivity to sulfonides or any component of brimonidine tartrate and timolol ophthalmic solution.
- •10.Use of intraocular corticosteroid implant at any time prior to baseline.
- •11.Use of contact lens within one week prior to baseline.
- •12.Ocular laser surgery within the 3 months prior to entry.
- •13.Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid.
- •14.Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose ( >1 g daily) salicylate therapy 3) monoamine oxidase (MAO) inhibitor therapy, 4) any antidepressant which affects noradrenergic transmission (e.g. tricyclic antidepressants, mianserin) or 5) adrenergicââ?¬â??augmenting psychotropic drug (e.g. desipramine, amitriptyline).
- •15.Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid.
- •16.Underwent within six months prior to baseline any other intraocular surgery (e.g., cataract surgery).
- •17.Underwent within 12 months prior to baseline: refractive surgery, filtering surgery for IOP reduction.
- •18.Amblyopia - only one sighted eye.
- •19.Clinically significant or progressive retinal disease (e.g., retinal degeneration, diabetic retinopathy, retinal detachment) in either eye.
- •20.Any abnormality preventing reliable applanation tonometry.
- •21.History or presence of significant alcoholism or drug abuse in the past one year.
- •22.Current history of smoking.
- •23.Active or prior severe, unstable, or uncontrolled cardiovascular, cerebrovascular, hepatic, or renal disease that would prevent safe administration of topical a-adrenergic agonists or carbonic anhydrase inhibitors, according to the investigator
- •24.Any form of glaucoma other than open-angle glaucoma.
- •25.Therapy with an investigational agent within the past 30 days from screening.
- •26.Clinically significant hematologic and or biochemical abnormalities based on laboratory testing.
- •27.Patients who are in the investigator s best judgment at risk of visual field or visual acuity worsening as a consequence of participation of trial.
- •28.Any other conditions, including severe illness, which would make the patient, in the opinion of the Investigator, unsuitable for the study.
- •29.Chronic use of any systemic medication that may affect IOP with less than three month stable dosing regimen i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha agonists, alpha-adrenergic blocking agen
研究者
相似试验
已完成
不适用
Bioequivalence study between Brinzolamide plus in adult patients with open-angle glaucoma or ocular hypertension.CTRI/2020/09/027727Pharmathen SA204
已完成
Unknown
A multicenter clinical trial for the comparison of efficacy and safety in the treatment of elevated intraocular pressure in adult patients with glaucoma.CTRI/2023/06/054478AZAD Pharma AG208
进行中（未招募）
不适用
A randomized, assessor-blinded, multicenter, international study investigating efficacy, patient's acceptance, safety and tolerability of Sodium Phosphate tablets compared to split dose Polyethylene Glycol for colon cleansing prior to colonoscopy.EUCTR2012-005115-13-ESABORATOIRES MAYOLY SPINDLER448
进行中（未招募）
2 期
KD2-396 IIPrevention of pertussis, diphtheria, tetanus, acute poliomyelitis, Hib infection and hepatitis BJPRN-jRCT2031230390Yasuhiko Shinmura150
已完成
3 期
To evaluate efficacy and safety of clobetasol propionate topical foam vs. clobetasol propionate lotion in patients with mild to moderate plaque type psoriasisCTRI/2017/10/010121Torrent Pharamceutical Ltd232